Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 31st:
ADMA Biologics, Inc. (ADMA - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
ADMA’s shares gained 52% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
Ekso Bionics Holdings, Inc. (EKSO - Free Report) : This exoskeleton products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.
Ekso Bionics’ shares gained 56.9% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
InhibikaseTherapeutics, Inc. (IKT - Free Report) : This clinical-stage pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.
Inhibikase’s shares gained 270.6% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of B.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 31st:
ADMA Biologics, Inc. (ADMA - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.
ADMA’s shares gained 52% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
Ekso Bionics Holdings, Inc. (EKSO - Free Report) : This exoskeleton products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.
Ekso Bionics’ shares gained 56.9% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.
InhibikaseTherapeutics, Inc. (IKT - Free Report) : This clinical-stage pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.
Inhibikase’s shares gained 270.6% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of B.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Just Released: Zacks Top 10 Stocks for 2024
Hurry – you can still get in early on our 10 top tickers for 2024. Hand-picked by Zacks Director of Research, Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2023, the Zacks Top 10 Stocks gained +974.1%, nearly TRIPLING the S&P 500’s +340.1%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2024. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>
Get the latest research report on ADMA - FREE
Get the latest research report on EKSO - FREE
Get the latest research report on IKT - FREE